These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

352 related articles for article (PubMed ID: 18250228)

  • 21. Impact of incorporating ABCB1 and CYP4F2 polymorphisms in a pharmacogenetics-guided warfarin dosing algorithm for the Brazilian population.
    Tavares LC; Duarte NE; Marcatto LR; Soares RAG; Krieger JE; Pereira AC; Santos PCJL
    Eur J Clin Pharmacol; 2018 Dec; 74(12):1555-1566. PubMed ID: 30051215
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Functional Characterization of 29 Cytochrome P450 4F2 Variants Identified in a Population of 8380 Japanese Subjects and Assessment of Arachidonic Acid
    Sato Y; Hishinuma E; Yamazaki S; Ueda A; Kumondai M; Saito S; Tadaka S; Kinoshita K; Nakayoshi T; Oda A; Maekawa M; Mano N; Hirasawa N; Hiratsuka M
    Drug Metab Dispos; 2023 Dec; 51(12):1561-1568. PubMed ID: 37775333
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effects of single nucleotide polymorphisms in c-Myc on stable warfarin doses in patients with cardiac valve replacements.
    Lee KE; Chang BC; Park S; Gwak HS
    Pharmacogenomics; 2015; 16(10):1101-8. PubMed ID: 26249541
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Interethnic variability of CYP4F2 (V433M) in admixed population of Roma and Hungarians.
    Sipeky C; Weber A; Melegh BI; Matyas P; Janicsek I; Szalai R; Szabo I; Varnai R; Tarlos G; Ganczer A; Melegh B
    Environ Toxicol Pharmacol; 2015 Jul; 40(1):280-3. PubMed ID: 26176903
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The frequency of CYP2C9, VKORC1, and CYP4F2 polymorphisms in Russian patients with high thrombotic risk.
    Ivashchenko D; Rusin I; Sychev D; Grachev A
    Medicina (Kaunas); 2013; 49(12):517-21. PubMed ID: 24858991
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A regression model to predict warfarin dose from clinical variables and polymorphisms in CYP2C9, CYP4F2, and VKORC1: Derivation in a sample with predominantly a history of venous thromboembolism.
    Wells PS; Majeed H; Kassem S; Langlois N; Gin B; Clermont J; Taljaard M
    Thromb Res; 2010 Jun; 125(6):e259-64. PubMed ID: 20421126
    [TBL] [Abstract][Full Text] [Related]  

  • 27. CYP2C9, VKORC1, and CYP4F2 polymorphisms and pediatric warfarin maintenance dose: a systematic review and meta-analysis.
    Takeuchi M; Kobayashi T; Biss T; Kamali F; Vear SI; Ho RH; Bajolle F; Loriot MA; Shaw K; Carleton BC; Hamberg AK; Wadelius M; Hirono K; Taguchi M; Wakamiya T; Yanagimachi M; Hirai K; Itoh K; Brandão LR; Ito S
    Pharmacogenomics J; 2020 Apr; 20(2):306-319. PubMed ID: 31673144
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Optimal dosing of warfarin and other coumarin anticoagulants: the role of genetic polymorphisms.
    Daly AK
    Arch Toxicol; 2013 Mar; 87(3):407-20. PubMed ID: 23376975
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Integrating interacting drugs and genetic variations to improve the predictability of warfarin maintenance dose in Chinese patients.
    Zhong SL; Yu XY; Liu Y; Xu D; Mai LP; Tan HH; Lin QX; Yang M; Lin SG
    Pharmacogenet Genomics; 2012 Mar; 22(3):176-82. PubMed ID: 22198820
    [TBL] [Abstract][Full Text] [Related]  

  • 30. VKORC1 and CYP2C9 genotypes are predictors of warfarin-related outcomes in children.
    Shaw K; Amstutz U; Hildebrand C; Rassekh SR; Hosking M; Neville K; Leeder JS; Hayden MR; Ross CJ; Carleton BC
    Pediatr Blood Cancer; 2014 Jun; 61(6):1055-62. PubMed ID: 24474498
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Pharmacogenetic relevance of CYP4F2 V433M polymorphism on acenocoumarol therapy.
    Pérez-Andreu V; Roldán V; Antón AI; García-Barberá N; Corral J; Vicente V; González-Conejero R
    Blood; 2009 May; 113(20):4977-9. PubMed ID: 19270263
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Characterization of a novel CYP2C9 gene mutation and structural bioinformatic protein analysis in a warfarin hypersensitive patient.
    Ciccacci C; Falconi M; Paolillo N; Oteri F; Forte V; Novelli G; Desideri A; Borgiani P
    Pharmacogenet Genomics; 2011 Jun; 21(6):344-6. PubMed ID: 21451434
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Genetic factors (VKORC1, CYP2C9, EPHX1, and CYP4F2) are predictor variables for warfarin response in very elderly, frail inpatients.
    Pautas E; Moreau C; Gouin-Thibault I; Golmard JL; Mahé I; Legendre C; Taillandier-Hériche E; Durand-Gasselin B; Houllier AM; Verrier P; Beaune P; Loriot MA; Siguret V
    Clin Pharmacol Ther; 2010 Jan; 87(1):57-64. PubMed ID: 19794411
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Computational analysis of missense variant CYP4F2*3 (V433M) in association with human CYP4F2 dysfunction: a functional and structural impact.
    Farajzadeh-Dehkordi M; Mafakher L; Samiee-Rad F; Rahmani B
    BMC Mol Cell Biol; 2023 May; 24(1):17. PubMed ID: 37161313
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Effect of gene polymorphims on the warfarin treatment at initial stage.
    Liu J; Jiang HH; Wu DK; Zhou YX; Ye HM; Li X; Luo ZY; Guo Z; Zhang YL; Wang YC; Zhang W; Zhou HH; Wang LS
    Pharmacogenomics J; 2017 Jan; 17(1):47-52. PubMed ID: 26644206
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Association of 1347 G/A cytochrome P450 4F2 (CYP4F2) gene variant with hypertension and stroke.
    Munshi A; Sharma V; Kaul S; Al-Hazzani A; Alshatwi AA; Shafi G; Koppula R; Mallemoggala SB; Jyothy A
    Mol Biol Rep; 2012 Feb; 39(2):1677-82. PubMed ID: 21625857
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Effects of NAD(P)H quinone oxidoreductase 1 polymorphisms on stable warfarin doses in Korean patients with mechanical cardiac valves.
    Chung JE; Chang BC; Lee KE; Kim JH; Gwak HS
    Eur J Clin Pharmacol; 2015 Oct; 71(10):1229-36. PubMed ID: 26257249
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Influence of NR3C1 and VDR polymorphisms on stable warfarin dose in patients with mechanical cardiac valves.
    Lee KE; Chung JE; Yi B; Cho YJ; Kim HJ; Lee GY; Kim JH; Chang BC; Gwak HS
    Int J Cardiol; 2017 Jun; 236():393-397. PubMed ID: 28262345
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effects of Pregnane X Receptor Genetic Polymorphisms on Stable Warfarin Doses.
    Moon JY; Chang BC; Lee KE; Bang JS; Gwak HS
    J Cardiovasc Pharmacol Ther; 2015 Nov; 20(6):532-8. PubMed ID: 25848132
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Worldwide allele frequency distribution of four polymorphisms associated with warfarin dose requirements.
    Ross KA; Bigham AW; Edwards M; Gozdzik A; Suarez-Kurtz G; Parra EJ
    J Hum Genet; 2010 Sep; 55(9):582-9. PubMed ID: 20555338
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.